Intriguingly, PD-L1 expression in tumors in this cohort was unrelated to clinical response, suggesting that data on CXCL9 levels in BALF might compensate for the shortcomings of the PD-L1 staining in patients with NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.